Supernus Pharmaceuticals, Inc. (SUPN) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Supernus Pharmaceuticals, Inc. (SUPN) Healthcare & Pipeline Overview

Supernus Pharmaceuticals, Inc. develops and commercializes treatments for central nervous system disorders, including epilepsy, ADHD, and Parkinson's disease. With a diverse portfolio of commercial products and a pipeline of drug candidates, Supernus aims to address unmet needs in the CNS market, competing with both generic and branded pharmaceutical companies.

What Is the Investment Thesis for SUPN?

Supernus Pharmaceuticals presents a notable research candidate based on its established portfolio of CNS products and a promising pipeline of drug candidates. The company's commercial products, including Qelbree for ADHD and treatments for Parkinson's Disease, generate consistent revenue streams. Upcoming catalysts include the potential approval and launch of SPN-830 for Parkinson's Disease. With a gross margin of 89.4%, Supernus demonstrates efficient operations. However, investors should be aware of the potential risks associated with regulatory approvals and competition from other pharmaceutical companies. The company's current market capitalization is $2.43B.

Based on FMP financials and quantitative analysis

SUPN Key Highlights

Gross Margin of 89.4% indicates strong pricing power and efficient cost management.

• Market Cap of $2.43B reflects investor confidence in the company's growth potential.
• Focus on CNS diseases addresses a significant market with unmet medical needs.
• Pipeline of product candidates offers potential for future revenue growth.
• Commercial products like Qelbree and Trokendi XR provide a stable revenue base.

Who Are SUPN's Competitors?

SUPN is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are SUPN's Key Strengths?

Diverse portfolio of commercial CNS products.

• Strong gross margin of 89.4%.
• Promising pipeline of drug candidates in clinical trials.
• Established commercial infrastructure and distribution network.

What Are SUPN's Weaknesses?

Reliance on a limited number of key products.

• Negative profit margin of -3.7%.
• Dependence on regulatory approvals for new products.
• Competition from larger pharmaceutical companies.

What Could Drive SUPN Stock Higher?

Potential FDA approval and launch of SPN-830 for Parkinson's Disease.

• Continued growth in sales of Qelbree for ADHD.
• Advancement of SPN-817 into later-stage clinical trials for severe epilepsy.
• Progress in the development of SPN-820 for resistant depression.

What Are the Key Risks for SUPN?

Negative return on equity (-10.4%) — the business is not currently generating profit on shareholder capital.

• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Insider selling — insiders were net sellers of roughly $6.1M recently.
• Unsuccessful clinical trials or regulatory setbacks for pipeline products.
• Patent expirations and generic competition for existing products.
• Competition from other pharmaceutical companies in the CNS market.
• Changes in healthcare regulations or reimbursement policies.
• Product liability claims.

What Are the Growth Opportunities for SUPN?

• Expansion of Qelbree into the adult ADHD market: Qelbree is currently approved for ADHD in pediatric patients. Expanding the indication to include adults represents a significant growth opportunity, as the adult ADHD market is underserved and growing. The market size for adult ADHD treatments is estimated to be worth billions of dollars annually. A successful expansion could significantly increase Qelbree's revenue potential within the next 2-3 years.
• Development and commercialization of SPN-830 for Parkinson's Disease: SPN-830 is a late-stage drug/device combination product candidate for the prevention of off episodes in Parkinson's Disease patients. This represents a significant unmet need in the PD market, as off episodes can severely impact patients' quality of life. The market for Parkinson's Disease treatments is expected to grow in the coming years, driven by an aging population. Approval and launch of SPN-830 could generate substantial revenue within the next 3-5 years.
• Advancement of SPN-817 for severe epilepsy: SPN-817 is a novel product candidate in Phase I clinical trials for the treatment of severe epilepsy. Epilepsy affects millions of people worldwide, and there is a need for more effective treatments, particularly for patients with severe or drug-resistant epilepsy. Successful development and commercialization of SPN-817 could address this unmet need and generate significant revenue in the long term (5-7 years).
• Development of SPN-820 for resistant depression: SPN-820 is a product candidate in Phase II clinical trials for treating resistant depression. Depression is a widespread mental health disorder, and many patients do not respond adequately to existing treatments. SPN-820 has the potential to provide a new treatment option for these patients. The market for depression treatments is large and growing. Successful development of SPN-820 could generate substantial revenue in the long term (5-7 years).
• Geographic expansion into international markets: Supernus currently focuses on the US market. Expanding into international markets, such as Europe and Asia, represents a significant growth opportunity. These markets have large populations and increasing healthcare spending. Successful geographic expansion could significantly increase Supernus's revenue potential over the next 5-10 years.

What Opportunities Does SUPN Have?

• Expansion of existing products into new indications.
• Geographic expansion into international markets.
• Strategic acquisitions of complementary businesses or product candidates.
• Partnerships with other pharmaceutical companies.

What Are SUPN's Competitive Advantages?

• Proprietary drug formulations and intellectual property protection.
• Established commercial infrastructure and distribution network.
• Strong relationships with healthcare providers and key opinion leaders.
• Expertise in developing and commercializing CNS drugs.

What Does SUPN Do?

Supernus Pharmaceuticals, Inc., founded in 2005 and headquartered in Rockville, Maryland, is a biopharmaceutical company dedicated to the development and commercialization of innovative treatments for central nervous system (CNS) diseases. The company's mission is to provide solutions for patients suffering from neurological and psychiatric disorders. Supernus has a portfolio of commercial products, including Trokendi XR and Oxtellar XR for epilepsy, Qelbree for ADHD, and APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER for Parkinson's Disease. These products address a range of CNS conditions and are marketed through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus continues to invest in research and development, with a pipeline of product candidates in various stages of clinical trials, including Qelbree (SPN-812) for ADHD, SPN-830 for Parkinson's Disease, SPN-817 for severe epilepsy, SPN-820 for resistant depression, and SPN-443 and SPN-446 for other CNS disorders. The company's focus on CNS diseases and its commitment to innovation position it as a key player in the specialty pharmaceutical market.

What Products and Services Does SUPN Offer?

• Develop and commercialize pharmaceutical products for central nervous system (CNS) disorders.
• Offer treatments for epilepsy, including Trokendi XR and Oxtellar XR.
• Provide Qelbree, a selective norepinephrine reuptake inhibitor for ADHD.
• Market APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER for Parkinson's Disease.
• Advance a pipeline of drug candidates in clinical trials for various CNS conditions.
• Focus on addressing unmet medical needs in neurology and psychiatry.
• Utilize pharmaceutical wholesalers, specialty pharmacies, and distributors to market their products.

How Does SUPN Make Money?

• Develop and obtain regulatory approval for novel pharmaceutical products.
• Manufacture and market these products to healthcare providers and patients.
• Generate revenue through sales of prescription medications.
• Invest in research and development to expand their product pipeline.

What Industry Does SUPN Operate In?

Supernus Pharmaceuticals operates in the specialty pharmaceutical industry, which is characterized by high research and development costs, stringent regulatory requirements, and intense competition. The market for CNS drugs is substantial and growing, driven by an aging population and increasing prevalence of neurological disorders. Supernus competes with both large pharmaceutical companies and smaller biotech firms, including AMRX: Amneal Pharmaceuticals, Inc. and LNTH: Lantheus Holdings, Inc. The company's focus on innovative formulations and targeted therapies differentiates it from generic drug manufacturers.

Who Are SUPN's Key Customers?

• Patients with central nervous system disorders, such as epilepsy, ADHD, and Parkinson's Disease.
• Healthcare providers, including neurologists, psychiatrists, and primary care physicians.
• Pharmaceutical wholesalers and distributors.
• Specialty pharmacies.

Company Profile

Supernus Pharmaceuticals, Inc. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Rockville, US. The company is led by CEO Jack A. Khattar. SUPN has traded publicly since 2012.

Return on equity for Supernus Pharmaceuticals, Inc. stands at -10.4%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -7.7%, showing how much profit it generates from its asset base. Its free cash flow yield is 0.8%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.08 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -4.5%, the inverse of the P/E and a quick read on earnings relative to price.

SUPN Valuation & Market Position

With a $2.43B market cap, Supernus Pharmaceuticals, Inc. sits in the mid-cap segment of the market. Analyst price targets span from $40.00 to $65.00, with a consensus of $57.60. At the current price of $41.90, that implies approximately 37% upside potential. Relative to its peer group, SUPN's quantitative score of 54/100 is roughly in line with the peer average of 64/100.

Quarterly Financial Performance: Supernus Pharmaceuticals, Inc.

Revenue for Supernus Pharmaceuticals, Inc. came in at $219.1M during Q2 FY2026, a 5.5% improvement versus the preceding quarter. The company recorded a net loss of $58.4M, with diluted EPS of $-1.01. Quarter-over-quarter revenue has been mixed, typical for a mid-cap company operating in Healthcare. Across the four most recent quarters, SUPN averaged $-0.48 in diluted EPS.

Supernus Pharmaceuticals, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 4.73 places it in the safe zone, indicating low near-term bankruptcy risk.

Supernus Pharmaceuticals, Inc. has beaten Wall Street's EPS estimate in 8 of its last 8 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 91.2% above estimates on average.

Over the past six months, Supernus Pharmaceuticals, Inc. insiders filed 42 SEC Form 4 transactions — 24 sales and 18 purchases. On net that is roughly 87K shares disposed (about $6.1M), a signal worth weighing alongside the fundamentals.

SUPN Financials

SUPN Latest News

SUPN Analyst Consensus

SUPN MoonshotScore

SUPN Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources